Salts of neuroceuticals and uses thereof

A salt of a neuroceutical and an acid, wherein:

• (a) the neuroceutical is selected from the group consisting of clozapine, quetiapine, risperidone, paliperidone, or olanzapine;
• and
• (b) the acid is selected from the group consisting of benzoic acid, nicotinic acid, and pantothenic acid;
• wherein
• (I) the molar ratio of the neuroceutical and the acid in the salt is 1:1 and the salt is selected from the group consisting of:
• a) a benzoic acid salt of clozapine, and wherein the salt comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 7.6, 12.4, 13.6, 15.3, 15.7, 16.0, 19.5, 19.9, 23.1, 24.9, 25.1, and 28.4 degrees;
• b) a nicotinic acid salt of clozapine, and wherein the nicotinic acid salt of clozapine comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 7.7, 8.2, 10.9, 12.6, 13.8, 16.0, 17.9, 18.2, 18.8, 19.5, 21.9, 22.2, 22.4, 23.3, 24.1, 25.2, 31.2, 31.5, 35.0, and 44.2 degrees;
• c) a nicotinic acid salt of quetiapine, and wherein the nicotinic acid salt of quetiapine comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 6.2, 9.2, 10.3, 11.4, 12.4, 12.9, 16.2, 16.5, 17.0, 17.2, 17.3, 17.5, 19.4, 19.9, 21.1, 21.3, 22.1, 27.1, 32.9, and 35.6 degrees;
• d) a nicotinic acid salt of risperidone, and wherein the nicotinic acid salt of risperidone comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 9.7, 10.9, 12.0, 12.4, 14.4, 17.1, 17.4, 24.4, 36.8, 42.8, and 44.1 degrees;
• and
• e) a benzoic acid salt of paliperidone, and wherein the benzoic acid salt of paliperidone comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 6.8, 9.0, 10.9, 11.4, 11.8, 16.6, 18.3, 18.6, 20.8, 22.2, 22.8, 27.5, 29.0, 30.3, and 32.3 degrees;
• or
• (II) the molar ratio of the neuroceutical and the acid in the salt is 1:2 and the salt is a nicotinic acid salt of paliperidone, and wherein the nicotinic acid salt of paliperidone comprises a solid form having a powder X-ray diffraction pattern, which comprises peaks at a reflection angle 2θ of approximately 6.7, 8.9, 11.0, 11.2, 11.7, 16.1, 16.4, 17.6, 18.4, 22.8, 27.2, and 29.9 degrees;
• or
• (III) the molar ratio of the neuroceutical and the acid in the salt is 5:1 and the salt is a pantothenic acid salt of olanzapine, and wherein the pantothenic acid salt comprises a solid form having a powder X-ray diffraction pattern, which comprises characteristic peaks at a reflection angle 2θ of approximately 7.7, 8.1, 8.7, 11.2, 11.7, 13.5, 15.4, 16.0, 16.2, 16.4, 19.0, 20.3, 22.2, 22.4, 23.1, 24.4, 25.7, 25.8, 26.7, 27.7, 29.4, 33.6, 34.3, 34.6, and 37.7 degrees.